Literatur
Eroglu Z et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 2018;553:347-50
Kendra KL et al. Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). J Clin Oncol 2022;40:9502
Patel SP et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-23
Garbe C et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 2023;29:1310-2.
El Sharouni MA et al. Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. J Am Acad Dermatol 2023;88:609-16
Forschner A et al. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications. J Dtsch Dermatol Ges 2020;18:1387-92
Drilon A et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018;378:731-9
Doebele RC et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hauschild, A. Schwierig zu therapierende Melanome. hautnah dermatologie 40 (Suppl 1), 10–13 (2024). https://doi.org/10.1007/s15012-023-8315-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15012-023-8315-2